Verve Therapeutics Prices of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its upsized underwritten public offering of 8,333,334 shares of its common stock at a public offering price of $27.00 per share, for total gross proceeds of approximately $225.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Verve. All of the shares in the offering are being sold by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to 1,250,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on July 25, 2022, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Jefferies, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering.

About Verve
Verve Therapeutics, Inc. is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease.